Clinical Trials

Enrolling

  • Sponsor: RegenexBio
    Protocol Number: RGX-314-3101

    A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD.

    Learn More

  • Sponsor: RegenexBio
    Protocol Number: RRGX-314-2104

    A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD

    Learn More

  • Sponsor: Affamed
    Protocol Number: AM712E1001

    A Prospective, Multi-Center, Open-label, Sequential, Multiple Ascending-Dose and Randomized Dose-Expansion Cohorts Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AM712 Following Intravitreal Administration in Patients with Neovascular Age-related Macular Degeneration.

    Learn More

  • Sponsor: Adverum Biotech
    Protocol Number: ADVM-022-11

     A Multi-Center, Randomized, Open Label Study of ADVM-022 (AAV. 7m8-aflibercept) in Neovascular (Wet) Age-related Macular Degeneration (nAMD)

    Learn More

  • Sponsor: Notal Vision
    Protocol Number: C2021.006

     The Evaluation of the Agreement and Precision of the Notal Vision Home OCT in the Automatic Fluid Quantification in Patients with NV-AMD

    Learn More

  • Sponsor: Opthea
    Protocol Number: OPT-302-1004

    A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

    Learn More

Ongoing

  • Sponsor: Amgen
    Protocol Number: ABP938

    A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration

    Learn More

  • Sponsor: Genentech
    Protocol Number: GR42691

    A Multicenter, Open-Label Extension Study to evaluate the long-term safety and tolerability of faricimab in patients with neovascular age-related macular degeneration (Avonelle-X)

    Learn More

  • Sponsor: Adverum Biotech
    Protocol Number: ADVM-022-07

    A Long-term study of ADVM-022 in Neovascular (WET) AMD- Optic Extension

    Learn More

  • Sponsor: Genentech
    Protocol Number: GR40549

     A Multicenter, Open-Label Extension study to evaluate the long-term safety and tolerability of the port delivery system with Ranibizumab in Patients with Neovascular age-related macular degeneration

    Learn More

Enrolling

  • Sponsor: Ionis
    Protocol Number: 696844-CS5

    A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

    Learn More

  • Sponsor: Janssen
    Protocol Number: HMR59?

    A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-Controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Advanced Age-related Macular Degeneration (AMD)

  • Sponsor: Genetech
    Protocol Number: GR42163

    A Phase Ia, Multicenter, open-label, single-dose, dose-escalation study of the safety, tolerability, Pharmacokinetics, and immunogenicity of intravitreal injections of R07303359 in Patients with Geographic Atrophy secondary to age-related macular degeneration

    Learn More

Ongoing

  • Sponsor: Alkeus
    Protocol Number: ALK-001

    A Phase 2/3 Multicenter, Randomized, Double-masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration

    Learn More

  • Sponsor: Apellis
    Protocol Number: APL-2-305

    A Phase 3, Open-Label, Multicenter, Extension study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration

    Learn More

  • Sponsor: Iveric
    Protocol Number: ISEE2008

     A Phase 3 Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

    Learn More

Ongoing

  • Sponsor: Genentech
    Protocol Number: GR41675

    A Phase III, Multicenter, Randomized study of the efficacy, safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Retinopathy (Pavilion)

    Learn More

Ongoing

  • Sponsor: Genentech
    Protocol Number: GR41986

    A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to evaluate the efficacy and safety of Faricimab in Patients with Macular Edema secondary to Central Retinal or Hemiretinal vein occlusion

    Learn More

Enrolling

  • Sponsor: Genentech
    Protocol Number: BP43445

    A phase II, multicenter, randomized, double masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7200220 administered intravitreally in patients with diabetic macular edema

    Learn More

Ongoing

  • Sponsor: Kodiak
    Protocol Number: KS301P104

    A Prospective, Randomized, Double-masked, Active comparator-controlled, multi-center, two-arm, Phase 3 Study to evaluate the efficacy and safety of Intravitreal KSI-301 compared with Intravitreal Aflibercept in Patients with Visual Impairment secondary to treatment-naive diabetic macular edema (DME)

    Learn More

  • Sponsor: Genentech
    Protocol Number: GR40550

    A phase III, multicenter, randomized, visual assessor-masked, active-comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in patients with diabetic macular edema (PAGODA)

    Learn More

  • Sponsor: Genentech
    Protocol Number: GR41987

    A multicenter, open-label extension study to evaluate the long-term safety and tolerability of faricimab in patients with diabetic macular edema

    Learn More

  • Sponsor: FFB
    Protocol Number: ProEyS024

    Rate of Progression in EYS Related Retinal Degeneration (Pro-EYS)

    Learn More

Enrolling

  • Sponsor: Acelyrin
    Protocol Number: 21103

    A Phase 2 Dose-finding Study to Evaluate the Efficacy, Safety, and Immunogenicity of Izokibep in Subjects with With Non-infectious Intermediate Uveitis, Posterior Uveitis or Panuveitis

    Learn More

  • Sponsor: Priovant
    Protocol Number: PVT-2201-201

    A Phase 2 Randomized, Double-Masked, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active Non-Infectious Intermediate-, Posterior-, and Panuveitis

    Learn More

Ongoing

  • Sponsor: UCSF
    Protocol Number: 17-23987

    Adalimumab in Juvenile Idiopathic Arthritis-associated uveitis Stopping Trial (ADJUST)

    Learn More

Securely text us at (303) 261-1600

For a quick response, securely text your Colorado Retina clinical care team at (303) 261-1600 during regular business hours for assistance with appointment scheduling, bill pay, insurance eligibility, assessment of symptoms, and anything in between.